Showing 301-310 of 1100 results for "".
DermwireTV 2024 Year in Review
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisWhat people want and why it matters
https://practicaldermatology.com/topics/general-topics/what-people-want-and-why-it-matters/19526/Our patients differ in both their skin biology and their use of skin care products on a daily basis. Discover how understanding the behaviors and practices of men and women can allow better and more effective product recommendations.Pros and Cons of DTC Advertising
https://practicaldermatology.com/topics/practice-management/pros-and-cons-of-dtc-advertising/18569/Hilary Baldwin, MD and James Q. Del Rosso, DO sit down with Derm Insider Host Neal Bhatia, MD to weigh the pros and cons of direct-to-consumer advertising on patients. They agree that if done well and with a primary focus on disease state rather than a specific drug, these ads can encourage patientsPatient Outreach Initiatives; Erelzi Approved
https://practicaldermatology.com/topics/practice-management/dermwiretv-patient-outreach-initiatives-erelzi-approved---etudruli/18580/DermatologistOnCall® Partners with NPF to enhance access to care for psoriasis. Vivacare Partners with NRS for patient education. Erelzi from Sandoz approved as biosimilar to Enbrel. And the FDA bans antibacterial ingredients from hand soaps; Calls for plain soap and water hand washing.Gold's Standards: Nashville's Laser Guru on Best Practices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/gold-s-standards-nashville-s-laser-guru-on-best-practices/18867/When a third of your practice is dedicated to energy-based devices, it's important to find the best solutions for your patient flow. In this edition of Best Practices, Joel L. Cohen, MD talks to Michael H. Gold, MD about his approach to adoption and promotion of energy-based devices. Dr. Gold discusSkin cancer: Coach's toughest opponent [Full-length]
https://practicaldermatology.com/topics/skin-cancer-photoprotection/skin-cancer-coach-s-toughest-opponent-full-length-/18921/Dr. Terrence Keaney created this PSA for his American Society for Dermatologic Surgery (ASDS) Future Leaders Network project. The PSA and video feature Division I college women's basketball coach Lisa Pace, who blames her indoor tanning habit for the development of more than 80 skin cancers, five ofSkin cancer: Coach's toughest opponent: PSA
https://practicaldermatology.com/topics/skin-cancer-photoprotection/skin-cancer-coach-s-toughest-opponent-psa/18922/Dr. Terrence Keaney created this PSA for his American Society for Dermatologic Surgery (ASDS) Future Leaders Network project. The PSA and video feature Division I college women's basketball coach Lisa Pace, who blames her indoor tanning habit for the development of more than 80 skin cancers, five ofHow to Integrate Physician-Dispensed Products
https://practicaldermatology.com/topics/general-topics/PD0609_10-php/22819/With the correct protocols, staff training, and product selection, physician dispensing can help retain your current patient base and assist in marketing to new patients.Cosmetic Dermatology: Ensuring Success at Any Level
https://practicaldermatology.com/topics/general-topics/PD0409_02-php/22840/In practice and perspective, a balanced approach to cosmetic and medical affairs coupled with a strong team ensures effective implementation of cosmetic services.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. June